University Of Southampton

A new drug, RI-AG03, targets tau proteins to potentially treat Alzheimer's by addressing two key areas, unlike previous drugs. Developed by international researchers, it showed promising results in extending fruit flies' lifespan with toxic tau tangles. Further studies in rodents and potential human trials are planned.

Researchers developed RI-AG03, a drug targeting two Alzheimer's disease 'hotspots' to block tau protein buildup, tested in lab dishes and fruit flies, showing promise in preventing neurodegeneration.

Researchers developed a drug, RI-AG03, targeting both key areas of Tau protein, effective in preventing Tau build-up in lab and fruit fly studies, potentially leading to more effective Alzheimer’s treatments.

Researchers developed a drug, RI-AG03, targeting tau protein clumping in Alzheimer’s disease, extending fruit fly lifespan and reducing tau aggregation in cells, with plans for rodent testing before clinical trials.

A new Alzheimer's drug, RI-AG03, targets two 'hotspots' on tau proteins, potentially slowing disease progression. Developed by international researchers, it differs from existing drugs like lecanemab and donanemab, which target amyloid. Early tests on fruit flies and human cells show promise, with plans for further rodent studies and potential human trials.

Researchers developed RI-AG03, a peptide inhibitor targeting both major Tau protein 'hotspots', preventing neurodegeneration in lab and fruit fly studies, marking a significant step in Alzheimer’s drug development.

Researchers developed a drug, RI-AG03, targeting both key areas of Tau proteins linked to Alzheimer’s, preventing their build-up in lab and fruit fly studies. The drug aims to address Tau aggregation, potentially leading to more effective treatments for neurodegenerative diseases.

A drug, RI-AG03, developed by an international team led by Lancaster University, targets both major aggregation-promoting 'hotspots' of the tau protein, key to Alzheimer's Disease. Effective in preventing tau buildup in lab and fruit fly studies, it could lead to more targeted and safer treatments for neurodegenerative diseases.

Researchers developed RI-AG03, a peptide inhibitor targeting both major Tau protein 'hotspots', effective in preventing Tau build-up in lab and fruit fly studies, potentially paving the way for Alzheimer's treatments.

Historian Alice Hunt launches 'Republic: Britain’s Revolutionary Decade 1649-1660' at P&G Wells Bookshop on Oct 3, 6pm. The book explores the interregnum's impact on British monarchy, politics, religion, and culture, challenging the inevitability of Charles II's restoration. Tickets for the launch are free but require booking.